Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brachytherapy With Durvalumab and Tremelimumab in Gynecological Malignancies
NCT04395079Phase 2Active, not recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Aug 2020
- Primary completion
- Oct 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in Gynecologic cancer, sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Aug 2020; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
Gynecologic cancer
Beyond the preview
Go deeper on NCT04395079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04395079.